Study of REGN1193 in Patients With Type 2 Diabetes Mellitus

Inclusion Criteria:

1. Metformin monotherapy at a dose of ≥1000 mg/day (up to the maximum daily dose of 2550
mg per day) for ≥8 weeks prior to randomization

2. Hemoglobin A1c value of ≥7.0% to ≤10.0%

3. Fasting plasma glucose value ≥130 mg/dL and ≤240 mg/dL

Exclusion Criteria:

1. Type 1 diabetes mellitus

2. Use of insulin or oral or injectable antihyperglycemic medications during the 8 weeks
prior to randomization

3. A severe hypoglycemic event in the 6 months prior to randomization

Note: The eligibility criteria listed above is not intended to contain all considerations
relevant to a patient's potential participation in a clinical trial therefore not all
inclusion/ exclusion criteria are listed.